These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 22044911)

  • 1. K-ras mutations in the plasma correspond to computed tomographic findings in patients with pancreatic cancer.
    Däbritz J; Preston R; Hänfler J; Oettle H
    Pancreas; 2012 Mar; 41(2):323-5. PubMed ID: 22044911
    [No Abstract]   [Full Text] [Related]  

  • 2. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival.
    Shin SH; Kim SC; Hong SM; Kim YH; Song KB; Park KM; Lee YJ
    Pancreas; 2013 Mar; 42(2):216-22. PubMed ID: 23344532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. K-ras mutations in circulating DNA from pancreatic and lung cancers: bridging methodology for a common validation of the molecular diagnosis value.
    Magistrelli P; Neri M; Granone P; Cesario A; Paleari L; Russo P
    Pancreas; 2008 Jul; 37(1):101-2. PubMed ID: 18580451
    [No Abstract]   [Full Text] [Related]  

  • 4. Early detection tools for pancreatic cancer.
    Schmidt C
    J Natl Cancer Inst; 2012 Aug; 104(15):1117-8. PubMed ID: 22851273
    [No Abstract]   [Full Text] [Related]  

  • 5. Results of a phase I trial of 12 patients with locally advanced pancreatic carcinoma combining gefitinib, paclitaxel, and 3-dimensional conformal radiation: report of toxicity and evaluation of circulating K-ras as a potential biomarker of response to therapy.
    Olsen CC; Schefter TE; Chen H; Kane M; Leong S; McCarter MD; Chen Y; Mack P; Eckhardt SG; Stiegmann G; Raben D
    Am J Clin Oncol; 2009 Apr; 32(2):115-21. PubMed ID: 19307945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorescence in situ hybridization and K-ras analyses improve diagnostic yield of endoscopic ultrasound-guided fine-needle aspiration of solid pancreatic masses.
    Reicher S; Boyar FZ; Albitar M; Sulcova V; Agersborg S; Nga V; Zhou Y; Li G; Venegas R; French SW; Chung DS; Stabile BE; Eysselein VE; Anguiano A
    Pancreas; 2011 Oct; 40(7):1057-62. PubMed ID: 21705950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
    Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
    Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma.
    Sinn BV; Striefler JK; Rudl MA; Lehmann A; Bahra M; Denkert C; Sinn M; Stieler J; Klauschen F; Budczies J; Weichert W; Stenzinger A; Kamphues C; Dietel M; Riess H
    Pancreas; 2014 May; 43(4):578-83. PubMed ID: 24681874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: a report of the PANDA study.
    Khalid A; Zahid M; Finkelstein SD; LeBlanc JK; Kaushik N; Ahmad N; Brugge WR; Edmundowicz SA; Hawes RH; McGrath KM
    Gastrointest Endosc; 2009 May; 69(6):1095-102. PubMed ID: 19152896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma.
    Ideno N; Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Tamura K; Aso T; Aishima S; Miyasaka Y; Ohuchida K; Ueda J; Takahata S; Oda Y; Mizumoto K; Tanaka M
    Pancreas; 2015 Mar; 44(2):311-20. PubMed ID: 25479586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased expression of DAB2IP in pancreatic cancer with wild-type KRAS.
    Duan YF; Li DF; Liu YH; Mei P; Qin YX; Li LF; Lin QX; Li ZJ
    Hepatobiliary Pancreat Dis Int; 2013 Apr; 12(2):204-9. PubMed ID: 23558076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
    Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S
    J BUON; 2013; 18(1):116-23. PubMed ID: 23613396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor mutation and pathologic-radiologic correlation between multiple lung nodules with ground-glass opacity differentiates multicentric origin from intrapulmonary spread.
    Chung JH; Choe G; Jheon S; Sung SW; Kim TJ; Lee KW; Lee JH; Lee CT
    J Thorac Oncol; 2009 Dec; 4(12):1490-5. PubMed ID: 19844187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of p16 and K-ras mutation in pancreatic adenocarcinoma and chronic pancreatitis differential diagnosis.
    Talar-Wojnarowska R; Gasiorowska A; Smolarz B; Romanowicz-Makowska H; Strzelczyk J; Janiak A; Kulig A; Malecka-Panas E
    J Physiol Pharmacol; 2004 Jul; 55 Suppl 2():129-38. PubMed ID: 15608367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic accuracy of K-ras mutation for pancreatic carcinoma: a meta-analysis.
    Liu SL; Chen G; Zhao YP; Wu WM; Zhang TP
    Hepatobiliary Pancreat Dis Int; 2013 Oct; 12(5):458-64. PubMed ID: 24103274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EUS-guided pancreatic fluid aspiration for DNA analysis of KRAS and GNAS mutations for the evaluation of pancreatic cystic neoplasia: a pilot study.
    Siddiqui AA; Kowalski TE; Kedika R; Roy A; Loren DE; Ellsworth E; Adler D; Finkelstein SD
    Gastrointest Endosc; 2013 Apr; 77(4):669-70. PubMed ID: 23498145
    [No Abstract]   [Full Text] [Related]  

  • 17. The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer.
    Mohelnikova-Duchonova B; Brynychova V; Hlavac V; Kocik M; Oliverius M; Hlavsa J; Honsova E; Mazanec J; Kala Z; Melichar B; Soucek P
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):669-82. PubMed ID: 23934321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with a KRAS mutation assay using allelic discrimination improves the diagnosis of pancreatic cancer.
    Bournet B; Selves J; Grand D; Danjoux M; Hanoun N; Cordelier P; Buscail L
    J Clin Gastroenterol; 2015 Jan; 49(1):50-6. PubMed ID: 24798941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer.
    Ogura T; Yamao K; Hara K; Mizuno N; Hijioka S; Imaoka H; Sawaki A; Niwa Y; Tajika M; Kondo S; Tanaka T; Shimizu Y; Bhatia V; Higuchi K; Hosoda W; Yatabe Y
    J Gastroenterol; 2013 May; 48(5):640-6. PubMed ID: 22983505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modified PNA-PCR method: a convenient and accurate method to screen plasma KRAS mutations of cancer patients.
    Yu S; Wu J; Xu S; Tan G; Liu B; Feng J
    Cancer Biol Ther; 2012 Mar; 13(5):314-20. PubMed ID: 22310974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.